Relmada Therapeutics Inc
NASDAQ:RLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Relmada Therapeutics Inc
Other
Relmada Therapeutics Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
Other
-$73k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other
-$260m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-16%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other
-$128m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-30%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other
-$459m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other
-$131m
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other
-$772m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-31%
|
|
Relmada Therapeutics Inc
Glance View
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Coral Gables, Florida and currently employs 10 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
See Also
What is Relmada Therapeutics Inc's Other?
Other
-73k
USD
Based on the financial report for Dec 31, 2025, Relmada Therapeutics Inc's Other amounts to -73k USD.
What is Relmada Therapeutics Inc's Other growth rate?
Other CAGR 1Y
75%
Over the last year, the Other growth was 75%.
